Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Astellas Pharma

Nine More Drugmakers Join the Medicaid Pricing Deals, and the Effect on Your Pharmacy Bill Is Limited

Nine more drugmakers signed most-favored-nation Medicaid pricing deals, bringing the total to 26. Here is what changes and what does not.

Medical Daily

Trump Has Now Struck Drug Pricing Deals With 26 Companies. They Cover Nearly 90% Of The Branded Drug Market.

Nine midsize drugmakers joined the White House program and pledged at least $19.6 billion in U.S. manufacturing investments.

International Business Times

Nine New Drugmakers Join Trump's Pricing Pact — But the Savings Remain Unproven

Nine more drugmakers joined Trump's MFN pricing deal, but the discounts flow through Medicaid — a program Texas and Florida never expanded.

Latin Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Pharma Giant Warns Pills Critical For Organ Transplant Patients' to Survive May Be Completely Empty in Urgent Recall

Pharmaceutical company Astellas Pharma announced two urgent recalls for vital immunosuppressive drugs, Prograf and Astagraf XL, that are used to prevent organ rejection in transplant recipients.

International Business Times

Japan PM demands release of businessman detained in China

Japan's Prime Minister Fumio Kishida said on Monday the government would continue to strongly demand that Beijing releases an Astellas Pharma employee detained in China, as fears remain over the safety of China's business environment.

Reuters

Japan foreign minister Hayashi to visit Beijing on Saturday

Japan Foreign Minister Yoshimasa Hayashi said on Friday he will visit Beijing for two days from Saturday to discuss a range of issues, including the detention of an Astellas Pharma Inc employee.

Reuters

Japanese man detained in China is Astellas Pharma employee - Kyodo

A Japanese man detained in China this month is a senior official of Astellas Pharma Inc, Kyodo news agency reported on Sunday citing a company spokesperson.

Reuters

Read news from The Economist, FT, and more,
with one subscription

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga

Astellas' Menopause Drug Suffers Setback After Failed Asian Trial

After acing a pair of phase 3 trials, Astellas Pharma Inc (OTC:ALPMF) has reported the failure of fezolinetant to beat placebo in a late-stage study of patients in Asia. The study randomized 302 women in China, Korea, and Taiwan. After 12 weeks, Astellas saw numerical improvements in the rate of hot flashes from baseline…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Amyotrophic lateral sclerosis

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.